2022
DOI: 10.1016/j.pupt.2022.102149
|View full text |Cite
|
Sign up to set email alerts
|

Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(12 citation statements)
references
References 36 publications
0
12
0
Order By: Relevance
“…Our study confirms the efficacy of NTD in slowing disease progression in terms of stabilizing lung function without, as already known, allowing a marked improvement in fibrotic damage. Patients with IPF may have a variable clinical course also influenced by comorbidities, smoking habits first and foremost, which affected 61% of the enrolled patients and by any NTD-associated therapies; however, the existence of a phenotype associated with a rapid decline in FVC leading rapidly to death, which occurred within a year in 5% of the cases in our cluster, should also be kept in mind [ 22 , 23 , 24 , 25 ]. In the studies performed in the 1990s and the early 2000s, before the era of the new American Thoracic Society (ATS)/European Respiratory Society (ERS) classification and the introduction of antifibrotic medication, the median survival of IPF patients was 2–3 years [ 26 , 27 , 28 ].…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…Our study confirms the efficacy of NTD in slowing disease progression in terms of stabilizing lung function without, as already known, allowing a marked improvement in fibrotic damage. Patients with IPF may have a variable clinical course also influenced by comorbidities, smoking habits first and foremost, which affected 61% of the enrolled patients and by any NTD-associated therapies; however, the existence of a phenotype associated with a rapid decline in FVC leading rapidly to death, which occurred within a year in 5% of the cases in our cluster, should also be kept in mind [ 22 , 23 , 24 , 25 ]. In the studies performed in the 1990s and the early 2000s, before the era of the new American Thoracic Society (ATS)/European Respiratory Society (ERS) classification and the introduction of antifibrotic medication, the median survival of IPF patients was 2–3 years [ 26 , 27 , 28 ].…”
Section: Discussionmentioning
confidence: 99%
“…FVC, FEV1, and DLCO were described as a percentage of the predicted values for the patient’s age, sex, and height [ 21 ]. Abnormalities of PFTs were defined as predicted values of forced vital capacity (FVC) < 80% and diffusing capacity of the lung for carbon monoxide (DLCO) < 70% [ 22 ].…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…Few cardiovascular events have been reported in patients treated with nintedanib in real-world studies [ 18 23 , 28 , 55 , 56 ]. In the largest real-world study to report data on cardiovascular events, among 244 patients treated with nintedanib for an average of 24 months at seven centres in Greece, ischaemic events (MI or ischaemic stroke) were reported in 2.9% of patients [ 28 ].…”
Section: Cardiovascular Eventsmentioning
confidence: 99%